Reverse DCF
What growth does the market imply for EXPLEOSOL?
Working backwards from the current price to find the FCF growth assumption baked in.
conservative
-7.5% implied annual FCF growth
The market is pricing in below-GDP growth — very conservative assumption. If the company delivers anywhere near its historical rate, there is significant upside.
Current Price
₹826
Historical Growth
8.3%
FCF Yield
13.39%
Price / FCF
7.5x
Plain English
To justify today's price of $825.50, EXPLEOSOL.NS needs to grow its free cash flow at -7.5% per year for the next 10 years. That is 15.8% slower than its historical growth rate of 8.3%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Implied | -7.5% | ₹829 | +0.4% |
| Half implied | -3.8% | ₹1,041 | +26.0% |
| Historical | 8.3% | ₹2,369 | +187.0% |
| GDP rate | 10.0% | ₹2,690 | +225.9% |
At Historical Growth Rate
It would take 3 years for EXPLEOSOL to organically grow into today's price assuming its historical FCF growth of 8.3%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.